Dinaciclib — drug · CancerIndex

Regulatory

Approvals (0)

Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.

Data not yet available

No regulatory approval recorded. Absence here is not evidence of absence: only ingested jurisdictions are covered.

What CancerIndex knows

Curated evidence below
Sources

Derived

Development pipeline

Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.

Scope	Stage	Max phase	Active	Phase 3	Trials	Jurisdictions	First approval	First trial
All cancers	Phase3	Phase 3	2	1	18	—	—	2006-08
Leukemia	Phase3	Phase 3	0	1	6	—	—	2006-08
Cutaneous Melanoma	Phase2	Phase 2	1	0	1	—	—	Jul 1, 2009
Malignant Lung Neoplasm	Phase2	Phase 2	0	0	1	—	—

Curated evidence

Clinical evidence (6)

CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.

civicCuratedShowing 1–6 of 6 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
CDK9 Overexpression2
Dinaciclib	Hepatocellular Carcinoma

Clinical trials

Trials with this intervention (18)

Most recently updated first, 50 per page.

clinicaltrialsPublishedShowing 1–18 of 18 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT00937937	Dinaciclib in Treating Patients With Stage IV Melanoma	active not recruiting	Phase 2	72	National Cancer Institute (NCI)NIH	1	Sep 14, 2026	clinicaltrials
NCT01434316	Veliparib and Dinaciclib in Treating Patients With Advanced Solid Tumors	active not recruiting	Phase 1	121

CCNE1 Amplification3
Dinaciclib	Malignant Ovarian Neoplasm	Predictive	D	Supports Sensitivity Response	1	submitted	EID7791 Small molecule inhibitors PHA-533533 and dinaciclib were used to treat CCNE1 amplified ovarian cancer cell lines. Inhibitors decreased pRb and increased apoptosis. PMID 24004674 · Etemadmoghadam et al., 2013 · Open in CIViC	civic
Cisplatin + DinaciclibCombination	Malignant Ovarian Neoplasm	Predictive	D	Supports Sensitivity Response	2	submitted	EID7799 Researchers tested the combination of dinaciclib + cisplatin in ovarian cancer cell lines and xenografts. p53 (-,-) mouse ovarian surface epithelial cells were transformed either by a CCNE1 transgene… (full text at CIViC) PMID 25557169 · Taylor-Harding et al., 2015 · Open in CIViC	civic
Akt Inhibitor MK2206 + DinaciclibCombination	Ovarian Serous Cystadenocarcinoma	Predictive	D	Supports Sensitivity Response	4	accepted	EID1735 A high throughput compound screen identified synergistic combinations in CCNE1 amplified high grade serous ovarian carcinoma, including dinaciclib and AKT inhibitors PMID 27663592 · Au-Yeung et al., 2017 · Open in CIViC	civic